



**NORTHSIDE HOSPITAL  
CANCER INSTITUTE**


BLOOD & MARROW TRANSPLANT  
PROGRAM

The Blood & Marrow  
Transplant Group  
OF GEORGIA



**NORTHSIDE HOSPITAL  
CANCER INSTITUTE**

LEUKEMIA PROGRAM



# Blood and Marrow Transplant Program

.....

## *Clinical Trial Opening*

Open to Enrollment: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Mantle Cell Lymphoma (MCL).

TGR-1202 is a newly developed drug that may stop cancer cells from growing based on recent laboratory experiments. The results from these experiments suggest this drug may help to kill cancer cells when coupled with ibrutinib. In this research study, the safety and tolerability of TGR-1202 is being investigated to determine the highest dose that can safely be used in combination with ibrutinib. The study is also aimed to evaluate whether TGR-1202 has any effect on tumor growth (nodal response), and to determine the overall response rate and duration of response in patients with CLL/SLL or MCL.

#### Primary Outcome Measures:

- MTD of TGR-1202

#### Secondary Outcome Measures:

- Overall Response Rate
- Rate of nodal response with lymphocytosis (nPR)
- Rate of Progression Free Survival
- Duration of Response

Please visit [ClinicalTrials.gov Identifier: NCT02268851](https://clinicaltrials.gov/ct2/show/study/NCT02268851) for additional information. To discuss study or eligibility, please contact Stacey Brown, NSH-BMT/Leukemia Clinical Research Manager, at 404-851-8238 or [Stacey.brown@northside.com](mailto:Stacey.brown@northside.com).